Clinical Trial Update: Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a neoadjuvant PD-1 monoclonal antibody in cisplatin-ineligible high-risk upper urinary tract urothelial carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Urinary Tract Urothelial Carcinoma
• Urothelial Carcinoma

Snippet

Sponsor: RenJi Hospital | Conditions: Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma | Phase 2 | Status: COMPLETED